Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

DO, MPH

Are IL-23 blockers as effective as TNF and IL-17 blockers at preventing the progression of PsA? 

JAK Inhibitors

You. The interleukin 1223 and the newer interleukin 23 blockers in their FDA approved dosing regimens actually do not inhibit radiographic progression of joint disease in psoriatic disease. Nevertheless, for example, an agent like gucelchumab in a different off label dosing regimen of 100 milligrams every four weeks. As you know, the standard dosing regimen is every eight weeks after a period of induction of zero week four, and then every eight weeks thereafter. The four week dosing regimen does demonstrate a radiographic inhibition of disease. In general, the class of 1223 and 23 blockers as well, do perform adequately in axial disease. But I think it's pretty clear from the literature, sure, that interleukin 17 blockers and our original TNF blockers appear to perform somewhat better in the management of the axial disease components of psoriatic arthritis.